By Marilynn Larkin June 04, 2021 NEW YORK (Reuters Health) – Two-phase 3, placebo-controlled studies suggest the oral Janus kinase (JAK) inhibitor upadacitinib is effective for moderate-to-severe atopic dermatitis (AD), both alone and with topical corticosteroids. “The results are highly robust and consistent among studies with really high efficacy and clearance rates that we have not seen...